Neurology

Neurology

If You Have Maternal Venezuelan Ancestry: What the FDA’s July 2026 Anesthesia Safety Alert Means for Families
July 27, 2026 5:02 pm

On July 2, 2026, the FDA said it is investigating rare, catastrophic neurologic outcomes after general anesthesia—especially involving sevoflurane/volatile anesthetics—in some people with maternal Venezuelan ancestry. Here’s what’s known, what remains uncertain, what professional guidance recommends discussing before surgery, and the stroke-like “red flags” that should trigger a call to 911 after anesthesia.

Read More If You Have Maternal Venezuelan Ancestry: What the FDA’s July 2026 Anesthesia Safety Alert Means for Families
Neurology

FDA Recall for a DBS Neurostimulator: How to Check Your Device
July 16, 2026 7:07 pm

Seeing an FDA recall record for an implanted deep brain stimulation (DBS) neurostimulator can be alarming. Here’s what the specific FDA record for Medtronic Kinetra model 7428 describes, how to check your device identifiers, and when symptom changes should trigger urgent care.

Read More FDA Recall for a DBS Neurostimulator: How to Check Your Device
Neurology

Shingles vaccine and dementia risk: promising signal, not proof
July 5, 2026 6:01 pm

A June 2026 study found lower dementia risk among some older adults who got Shingrix after a skilled-nursing-facility stay. But in the U.S., the proven reason to get the shingles vaccine is still preventing shingles and its complications—not preventing dementia.

Read More Shingles vaccine and dementia risk: promising signal, not proof
Neurology

Can the shingles vaccine lower dementia risk? What newer U.S. studies show
June 22, 2026 5:01 pm

New U.S. studies found lower dementia diagnosis rates after Shingrix, but they do not prove the vaccine prevents dementia. Here is what adults 50 and older should know now.

Read More Can the shingles vaccine lower dementia risk? What newer U.S. studies show
Neurology

After a TIA or clot-caused stroke, should you ask about asundexian?
June 10, 2026 4:40 pm

A large 2026 trial suggests investigational asundexian may lower repeat stroke risk after certain recent strokes or high-risk TIAs without more major bleeding. It is worth asking about, but not a reason to change medicines on your own.

Read More After a TIA or clot-caused stroke, should you ask about asundexian?
Neurology

Auvelity for Alzheimer’s agitation: what families should know
June 9, 2026 6:08 pm

Auvelity is now FDA-approved for agitation associated with dementia due to Alzheimer’s disease. Here is what families should know about who it is for, how it was studied, the main risks, why it is not a rescue medicine, and why medical evaluation and non-drug support still matter.

Read More Auvelity for Alzheimer’s agitation: what families should know
Neurology

Do newer CGRP migraine medicines raise heart risk?
May 27, 2026 5:25 pm

A new observational Neurology study is raising a question many migraine patients will ask: do CGRP preventive medicines increase cardiovascular risk? The short answer is that the study found an association, but it did not prove cause and effect, and the absolute risk increase was small.

Read More Do newer CGRP migraine medicines raise heart risk?
Neurology

Frequent migraines? New prevention studies may help guide choices
May 6, 2026 4:47 pm

New migraine-prevention research adds to the evidence that some people do better with CGRP-targeting medicines, onabotulinumtoxinA, or older oral options. But the best choice still depends on migraine pattern, side effects, cost, and other health conditions.

Read More Frequent migraines? New prevention studies may help guide choices
Clinical Trials | Headache | Neurology | Pediatric

A New Migraine Prevention Option for Some Kids: What the Latest Ajovy Study Means for Families
March 29, 2026 5:41 pm

A newly published New England Journal of Medicine trial adds stronger evidence behind Ajovy for some children and teens with episodic migraine. The study found modest average benefit, not a cure, and the current U.S. label applies only to patients ages 6 to 17 who weigh 45 kg or more.

Read More A New Migraine Prevention Option for Some Kids: What the Latest Ajovy Study Means for Families
Blood | Dementia | Medical Devices & Diagnostics | Neurology

Alzheimer’s Blood Tests Are Moving Closer to Everyday Care: What They Can Tell You, and What They Still Can’t
March 25, 2026 10:55 amMarch 25, 2026 10:38 pm

Roche’s FDA-cleared pTau181 blood test brings Alzheimer’s biomarker testing closer to everyday care, but right now it is mainly for adults 55 and older who already have cognitive symptoms, and a positive result still usually needs more workup. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K252163))

Read More Alzheimer’s Blood Tests Are Moving Closer to Everyday Care: What They Can Tell You, and What They Still Can’t
Dementia | Medicare & CMS Updates | Neurological Disorders | Neurology

Alzheimer’s Anti-Amyloid Drugs in 2026: Who Qualifies, What Are the Risks, and What Medicare Covers
March 20, 2026 11:13 pmMarch 25, 2026 10:40 pm

FDA-approved anti-amyloid drugs such as lecanemab are now in real-world use for early Alzheimer’s disease. Here’s who qualifies, what the main clinical trial showed, what ARIA risks mean, and how Medicare coverage works in the United States.

Read More Alzheimer’s Anti-Amyloid Drugs in 2026: Who Qualifies, What Are the Risks, and What Medicare Covers
Dementia | Medicare & CMS Updates | Neurological Disorders | Neurology

Anti-Amyloid Antibodies for Early Alzheimer’s: What FDA Approval Means for Patients, Risks, and Access in 2026
March 20, 2026 11:11 pmMarch 25, 2026 10:40 pm

FDA traditional approval of lecanemab for early Alzheimer’s disease offers modest slowing of decline for some patients—but requires careful screening, MRI monitoring, and meeting Medicare coverage rules. Here’s what families should understand in 2026.

Read More Anti-Amyloid Antibodies for Early Alzheimer’s: What FDA Approval Means for Patients, Risks, and Access in 2026
Drug Safety & Recalls | Headache | Neurological Disorders | Neurology

When Headache Medicine Backfires: What to Know About Medication Overuse Headache
March 20, 2026 9:58 pmMarch 25, 2026 10:41 pm

Using headache medicines too often can sometimes make headaches worse instead of better. Here’s what U.S. experts say about medication overuse headache—how it happens, who’s at risk, and how to break the cycle safely.

Read More When Headache Medicine Backfires: What to Know About Medication Overuse Headache
Dementia | Medicare & CMS Updates | Neurological Disorders | Neurology

Alzheimer’s Antibody Drugs in 2026: What Medicare Covers, Who Qualifies, and What Patients Should Know
March 20, 2026 9:27 pmMarch 25, 2026 10:41 pm

Anti-amyloid antibody treatments such as lecanemab are now part of Alzheimer’s care in the United States—but only for certain patients. Here’s who qualifies, what Medicare covers, how MRI safety monitoring works, and what families should realistically expect.

Read More Alzheimer’s Antibody Drugs in 2026: What Medicare Covers, Who Qualifies, and What Patients Should Know
Brain | Dementia | Medicare & CMS Updates | Neurology

Anti-Amyloid Alzheimer’s Drugs in 2026: Who Qualifies, What They Do, and What Families Should Know
March 20, 2026 9:18 pmMarch 25, 2026 10:42 pm

FDA-approved anti-amyloid drugs like lecanemab can modestly slow early Alzheimer’s disease—but they are not cures. Here’s who qualifies, what the clinical trials showed, the real risks, and how Medicare coverage works in 2026.

Read More Anti-Amyloid Alzheimer’s Drugs in 2026: Who Qualifies, What They Do, and What Families Should Know
Brain | Hypertension | Neurology | Public Health

Stroke in the United States: What the Latest CDC Data Means for Your Brain Health
March 14, 2026 11:39 pmMarch 25, 2026 10:46 pm

Stroke remains a leading cause of death and long-term disability in the United States. Here’s what the most recent CDC data shows, who is at highest risk, and what everyday prevention steps can lower your chances.

Read More Stroke in the United States: What the Latest CDC Data Means for Your Brain Health
Medical Mysteries | Medical Research & Studies | Neurological Disorders | Neurology

Why Some People Never Feel Pain: What Congenital Insensitivity to Pain Teaches Us About the Human Body
March 14, 2026 11:34 pmMarch 25, 2026 10:46 pm

A rare condition called congenital insensitivity to pain may sound like a superpower. In reality, it can be life-threatening. Here’s what researchers know, what remains a mystery, and what it means for everyday health.

Read More Why Some People Never Feel Pain: What Congenital Insensitivity to Pain Teaches Us About the Human Body
Hearing Loss | Neurology | Pediatrics | Public Health

Hearing Loss in the U.S.: What Public Health Experts Want Families to Know in 2026
March 14, 2026 11:23 pmMarch 25, 2026 10:46 pm

Hearing loss affects millions of Americans across all ages. Here’s what current public health guidance says about causes, prevention, over-the-counter hearing aids, and when to seek care.

Read More Hearing Loss in the U.S.: What Public Health Experts Want Families to Know in 2026
Brain | Headache | Medical Care | Neurology

Headaches in 2026: When to Worry, What Works, and What the Evidence Says
March 14, 2026 11:18 pmMarch 25, 2026 10:46 pm

Headaches are common, but not all are the same. Here’s what U.S. health experts say about types of headaches, warning signs, treatment options, and when to seek medical care.

Read More Headaches in 2026: When to Worry, What Works, and What the Evidence Says
Brain | Dementia | Neurology | Public Health

Brain Health in 2026: What the Latest Public Health Guidance Says About Protecting Your Mind
March 14, 2026 11:06 pmMarch 25, 2026 10:47 pm

New and ongoing guidance from U.S. public health agencies highlights practical steps people can take to lower their risk of stroke, dementia, and other brain-related conditions. Here’s what matters most for everyday life.

Read More Brain Health in 2026: What the Latest Public Health Guidance Says About Protecting Your Mind
Brain | Dementia | Elderly | Neurology

Brain Health in 2026: What the Evidence Says About Lowering Dementia Risk
March 14, 2026 10:45 pmMarch 25, 2026 10:47 pm

Dementia is not an inevitable part of aging. Here’s what major public health agencies and medical journals say about protecting brain health—and what it means for you and your family.

Read More Brain Health in 2026: What the Evidence Says About Lowering Dementia Risk
Elderly | Hearing Loss | Mental Health | Neurology

Hearing Loss in the United States: What’s New, Who’s at Risk, and What You Can Do
March 14, 2026 10:44 pmMarch 25, 2026 10:48 pm

Hearing loss affects millions of Americans across all ages. Here’s what the latest federal guidance and research say about risk factors, over-the-counter hearing aids, prevention, and when to seek care.

Read More Hearing Loss in the United States: What’s New, Who’s at Risk, and What You Can Do

End of content